WallStSmart

Eli Lilly and Company (LLY)vsStevanato Group SpA (STVN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 6827% more annual revenue ($86.46B vs $1.25B). LLY leads profitability with a 31.9% profit margin vs 11.3%. LLY appears more attractively valued with a PEG of 1.33. LLY earns a higher WallStSmart Score of 74/100 (B).

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

STVN

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

STVNUndervalued (+67.9%)

Margin of Safety

+67.9%

Fair Value

$48.58

Current Price

$15.53

$33.05 discount

UndervaluedFair: $48.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

STVN2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

STVN2 concerns · Avg: 3.5/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bull Case : STVN

The strongest argument for STVN centers on Debt/Equity, Price/Book.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Bear Case : STVN

The primary concerns for STVN are PEG Ratio, Piotroski F-Score.

Key Dynamics to Monitor

LLY profiles as a growth stock while STVN is a value play — different risk/reward profiles.

STVN carries more volatility with a beta of 0.80 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 59/100), backed by strong 31.9% margins and 38.6% revenue growth. STVN offers better value entry with a 67.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.

Want to dig deeper into these stocks?